



## FOR IMMEDIATE RELEASE

### **Axxam SpA expands to Denmark; opens office in Copenhagen.**

**September 27<sup>th</sup>, 2018** - Axxam SpA (Milan/Italy), a privately-owned innovative Partner Research Organization (iPRO) with a strong and leading expertise for the identification and characterization of bioactive compounds, announced this month the opening of its first Scandinavian office, located in the Copenhagen Bioscience Park (COBIS) in Copenhagen, Denmark.

*“Copenhagen was the right choice for our first office in the Nordic countries”* said Dr. Stefan Lohmer, co-founder and CEO of Axxam. *“Copenhagen is evolving as a biotechnology center and we want to be able to work face-to-face with our clients and partners, sharing expertise. Our new facility at COBIS will bring us closer to the important Nordic life science, pharma and biotech environment, and I believe that this region will fit extremely well with our iPRO approach. Many early stage companies would benefit from our expertise to identify bioactive compounds for their innovative targets using our HTS/HCS platforms and compound collections. Through our local presence we want to increase the important direct interaction with start-up companies, VCs and pharma/biotech companies.”*

Katherina Orellana, Business Development Manager, will be managing this office which is based at COBIS, Ole Maaløes Vej 3, 2200 Copenhagen DENMARK and can be contacted by email: [katherina.orellana.ko@axxam.com](mailto:katherina.orellana.ko@axxam.com) or phone: +39 3450877606.

#### **About Axxam S.p.A.**

Axxam is an innovative Partner Research Organization (iPRO). We are a leading provider of integrated discovery services across Life Sciences industries including: pharmaceuticals, crop protection, animal health, cosmetics, fragrances, food and beverages. We have consolidated expertise across a broad range of discovery disciplines and innovative technologies including: assay development, high-throughput screening of both the Axxam high quality compound collections (synthetic and natural) or those provided by our clients, compound management, hit identification and hit validation. Our performance-driven approach has been recognized by our clients as key to the success for their discovery programs. Axxam is also engaged in alliance-based research towards innovative small molecule therapies for diseases with a high unmet medical need. Axxam’s business terms are flexible, ranging from fee-for-service to risk-sharing deal structures.